Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares) (ITUB) vs Johnson & Johnson (JNJ) Price & Performance

Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares)Trade
Johnson & JohnsonTrade

Price performance (Past 24H)

Key statistics

Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares) vs Johnson & Johnson — how do they compare? Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares) trades at $9.95 (market cap $112.95B), while Johnson & Johnson trades at $258.89 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 5.5× Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares)'s market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares) for 0 Days and Johnson & Johnson for 129 Days on average.

ITUBJNJ
Market Cap
$112.95B$618.09B
Volume
44,012,2036,050,983
Sector
FinancialsHealth
52-Week High
$10.15$278.43
52-Week Low
$6.76$186.00
Typical Hold Time
0 Days129 Days
Enterprise Value
$1.33T$646.37B
Dividend Yield
1.74%2.09%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares)

No Aura AI signal available yet.

Johnson & Johnson

Johnson & Johnson (JNJ) trades at $258.45, up 1.44% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and robust cash flow. Analyst consensus is bullish with a $286.53 price target, though technical indicators show resistance near $260. Recent news highlights pipeline strength including Icotyde's potential $4.5B peak sales.

JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and competitive pressures. The stock presents value near current levels with 10.7% upside to consensus target, though technical weakness suggests potential near-term consolidation. Long-term growth drivers include oncology portfolio and Ottava surgical system development.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

ITUB
100% Buy0% Sell
Avg holding period · 0 Days
JNJ
96% Buy4% Sell
Avg holding period · 129 Days

Top news

Latest headlines on both assets

About Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares)

Itaú Unibanco is a Brazilian financial services company providing banking, credit, insurance, and investment products. It serves individual, business, and corporate clients.

Read more on ITUB →

About Johnson & Johnson

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.

Read more on JNJ →